Appointment of Non-Executive Director

Proteome Sciences PLC

16 September 2026

 

16 September 2026     

 The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the UK Market Abuse Regulation

Proteome Sciences plc

(“Proteome Sciences” or the “Company”)

Appointment of Non-Executive Director

Proteome Sciences plc (AIM:PRM) is pleased to announce the appointment of Helen Spice FCA as an independent non-executive director of the Company, with immediate effect.

Helen Spice had a successful accountancy career at KPMG where she was appointed CFO of KPMG International from 2008 to 2015. She is currently a non-executive director at Barts Health NHS Trust and recently retired from Great Western Hospitals NHS Foundation Trust, where her role included Chair of the Audit, Risk and Assurance Committee. She brings strong strategic, financial and accounting experience to the Company. 

The following disclosures are made pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:

Helen Braidwood Spice, aged 61, currently holds or has held the following directorships or partnerships in the past five years:

Current	Past five years
Barts Health NHS Trust	Great Western Hospitals NHS Foundation Trust Make-a-Wish Foundation UK Mental Health and Employment Partnership Limited

Helen Spice does not currently hold any ordinary shares, options or warrants in the Company.

There are no further disclosures required in accordance with AIM Rule 17 or Schedule Two, paragraph (g) of the AIM Rules for Companies.

Enquiries:

Proteome Sciences plc
Christopher Pearce, Executive Chairman	Tel: [phone]
Richard Dennis, Chief Commercial Officer
SP Angel Corporate Finance LLP (Nominated Adviser & Broker)

David Hignell/Matthew Johnson (Corporate Finance) Vadim Alexandre (Corporate Broking)

Tel: [phone]

About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, with analysis using a range of depletion strategies in combination with TMTcalibrator™ providing access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Chemoproteomics using Solvent Shift reveals the selectivity that drugs have to binding one or more proteins in the sample proteome.  Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

Further information on the Company can be found on its website at: https://www.proteomics.com/

The Company's LEI is 213800Q62ICXANKU2986.

 

END